{"TopicDetails": {"type": 0, "ccm2Id": 46939098, "cftId": 0, "identifier": "HORIZON-MISS-2024-CANCER-01-05", "title": "Improving the understanding and management of late-effects in adolescents and young adults (AYA) with cancer", "publicationDateLong": 1713398400000, "callIdentifier": "HORIZON-MISS-2024-CANCER-01", "callTitle": "Research and Innovation actions supporting the implementation of the Mission on Cancer", "callccm2Id": 46939155, "allowPartnerSearch": true, "frameworkProgramme": {"id": 43108390, "abbreviation": "HORIZON", "description": "Horizon Europe Framework Programme (HORIZON)"}, "programmeDivision": [{"id": 43108557, "abbreviation": "HORIZON.2.1", "description": "Health"}, {"id": 43108541, "abbreviation": "HORIZON.2", "description": "Global Challenges and European Industrial Competitiveness"}], "missionDetails": "<p>The goal of the Mission on Cancer is to improve the lives of more than 3 million people by 2030, through prevention, cure and for those affected by cancer including their families, to live longer and better. The objectives include: Understand; Prevent what is preventable; Optimise diagnostics and treatment; Support quality of life; Ensure equitable access in all aforementioned areas. The Mission on Cancer will address all cancers including poorly-understood cancers[[<sup> </sup>Includes refractory cancers or cancer subtypes, at any stage of the disease in any age group and part of society with a 5-year overall survival that is less than 50% from time of diagnosis.]] in men and women, cancers in children, adolescents and young adults as well as in the elderly, cancers in socio-economically vulnerable populations, living in either cities, rural or remote areas, across all Member States and Associated countries.</p><p>The Mission on Cancer is implemented using a health-in-all policies approach[[<sup> </sup>Health in All Policies is an approach to public policies across sectors that systematically takes into account the health implications of decisions, seeks synergies, and avoids harmful health impacts in order to improve population health and health equity. <a href=\"https://www.who.int/social_determinants/publications/health-policies-manual/key-messages-en.pdf\">https://www.who.int/social_determinants/publications/health-policies-manual/key-messages-en.pdf</a>]]; through infrastructure support; regional, social and citizen community development; through investments; support and commitments from public and private sources, including from Member States, Associated countries and industry; through cooperation with third countries; and through synergies with other existing EU programmes including EU4HEALTH, EURATOM, Digital Europe, Erasmus+, the EU Strategic Framework on Health and Safety at Work 2021-2027 and other initiatives related to cancer.</p><p>It also relates to the European Green Deal, including the Farm to Fork strategy[[<sup> </sup><a href=\"https://ec.europa.eu/food/farm2fork_en\">https://ec.europa.eu/food/farm2fork_en</a>]]. The mission proposes research and policy directions and objectives to identify effective strategies for the development and implementation of cancer prevention, including on environmental factors (e.g. exposure to workplace carcinogens, air pollution, unhealthy diet, nutrition and low physical activity).</p><p>Furthermore, it is also in line with the industrial[[<sup> </sup><a href=\"https://ec.europa.eu/info/strategy/priorities-2019-2024/europe-fit-digital-age/european-industrial-strategy_en\">https://ec.europa.eu/info/strategy/priorities-2019-2024/europe-fit-digital-age/european-industrial-strategy_en</a>]] and digitalisation strategy[[<sup> </sup><a href=\"https://ec.europa.eu/info/strategy/priorities-2019-2024/europe-fit-digital-age_en\">https://ec.europa.eu/info/strategy/priorities-2019-2024/europe-fit-digital-age_en</a>]]. The mission proposes a further upscaling and digitalisation of services, innovation in diagnostics and interventions, and establishing living labs, contributing to the positive impact of efforts by industry and SMEs on the health of citizens. Envisaged opportunities are in the fields of: cancer biomarkers; cloud computing and digital applications, smart apps/sensors. The mission also supports the integration of AI, machine learning and deep learning approaches to facilitate a better understanding of cancer, to improve prevention screening and early detection, diagnosis, clinical decision-making, administration of combinational therapies, and clinical management of patients living with and after cancer.</p><p>Calls for proposals under this mission should contribute to setting out a credible pathway for implementing the Mission on Cancer, thereby contributing to mission objectives.</p><p>Proposals for topics under this Mission should set out a credible pathway to improving Cancer control, and more specifically to all of the following impacts:</p><ul level=\"0\"><li>Improve understanding of the development of cancer in the context of the environment, work, and lifestyle in the broadest possible sense,</li><li>Enhance cross-policy cancer prevention strategies,</li><li>Optimise the diagnostics and treatment of cancer based on the principle of equitable access,</li><li>Improve the quality of life of cancer patients, survivors and their families through widely analysing all key factors and needs that are related to the quality of life,</li><li>Accelerate the digital transformation of research, innovation and health systems.</li> </ul><p>The implementation plan specifies the goal and four main objectives as well as implementation details of the Mission on Cancer[[<a href=\"https://ec.europa.eu/info/sites/default/files/research_and_innovation/funding/documents/cancer_implementation_plan_for_publication_final_v2.pdf\">https://ec.europa.eu/info/sites/default/files/research_and_innovation/funding/documents/cancer_implementation_plan_for_publication_final_v2.pdf</a>]].</p><p>In the calls described below, the Commission envisages several actions[[<sup> </sup>The listed areas for potential actions are tentative and non-binding.]]: On the Cancer Mission objective <em>Understanding</em>, the Commission plans to address tumour-host interactions to enhance prevention, treatment and care interventions in poorly-understood childhood as well as adult cancer patients. On the Cancer Mission objective <em>Prevention</em>, the Commission foresees an action on behaviour change. On the Cancer Mission objective <em>Diagnosis and treatment</em>, the Commission envisages an action on minimally invasive diagnostics, which will also improve the quality of life. On the Cancer Mission objective <em>Quality of life</em>, the Commission envisages to enhance the quality of life for survivors of childhood cancer by setting up oncology-centred living labs. The society will benefit from a reduced burden of cancer and solving healthcare barriers.</p>", "missionDescription": "Mission: Cancer (2023/24)", "topicMGAs": [], "tags": ["fatigue", "childhood cancer", "cancer care", "cancer", "late-effects of cancer treatment", "cancer patient", "Adolescent and Young Adult (AYA) cancer", "mental health", "quality of life", "chronic pain", "infertility"], "keywords": ["Rehabilitation", "Quality of health care", "Rights of the child", "School education", "Health inequalities", "EOSC and FAIR data", "Artificial Intelligence", "Special Needs Education", "Child health", "Public health", "Digital Agenda"], "flags": ["EoscAndFairData", "AI", "DigitalAgenda"], "sme": false, "actions": [{"status": {"id": 31094502, "abbreviation": "Open", "description": "Open"}, "types": [{"typeOfAction": "HORIZON-RIA HORIZON  Research and Innovation Actions", "typeOfMGA": [{"id": 43027846, "abbreviation": "HORIZON-AG", "description": "HORIZON Action Grant Budget-Based"}]}], "plannedOpeningDate": "18 April 2024", "submissionProcedure": {"id": 31094504, "abbreviation": "single-stage", "description": "single-stage"}, "deadlineDates": ["18 September 2024"]}], "latestInfos": [], "budgetOverviewJSONItem": {"budgetTopicActionMap": {"3523464": [{"action": "HORIZON-MISS-2024-CANCER-01-04 - HORIZON-CSA HORIZON Coordination and Support Actions", "plannedOpeningDate": "18 April 2024", "deadlineModel": "single-stage", "deadlineDates": ["18 September 2024"], "budgetYearMap": {"2024": 2999999.9}, "expectedGrants": 1, "minContribution": 3000000, "maxContribution": 3000000, "budgetTopicActionMap": {}}], "3523468": [{"action": "HORIZON-MISS-2024-CANCER-01-05 - HORIZON-RIA HORIZON  Research and Innovation Actions", "plannedOpeningDate": "18 April 2024", "deadlineModel": "single-stage", "deadlineDates": ["18 September 2024"], "budgetYearMap": {"2024": 35999999.98}, "expectedGrants": 6, "minContribution": 4000000, "maxContribution": 6000000, "budgetTopicActionMap": {}}], "3523472": [{"action": "HORIZON-MISS-2024-CANCER-01-02 - HORIZON-CSA HORIZON Coordination and Support Actions", "plannedOpeningDate": "18 April 2024", "deadlineModel": "single-stage", "deadlineDates": ["18 September 2024"], "budgetYearMap": {"2024": 2999999.9}, "expectedGrants": 1, "minContribution": 3000000, "maxContribution": 3000000, "budgetTopicActionMap": {}}], "3523476": [{"action": "HORIZON-MISS-2024-CANCER-01-01 - HORIZON-RIA HORIZON  Research and Innovation Actions", "plannedOpeningDate": "18 April 2024", "deadlineModel": "single-stage", "deadlineDates": ["18 September 2024"], "budgetYearMap": {"2024": 30000000.0}, "expectedGrants": 1, "minContribution": 30000000, "maxContribution": 30000000, "budgetTopicActionMap": {}}], "3523480": [{"action": "HORIZON-MISS-2024-CANCER-01-03 - HORIZON-IA HORIZON Innovation Actions", "plannedOpeningDate": "18 April 2024", "deadlineModel": "single-stage", "deadlineDates": ["18 September 2024"], "budgetYearMap": {"2024": 34999999.95}, "expectedGrants": 3, "minContribution": 10000000, "maxContribution": 12000000, "budgetTopicActionMap": {}}], "3523484": [{"action": "HORIZON-MISS-2024-CANCER-01-06 - HORIZON-IA HORIZON Innovation Actions", "plannedOpeningDate": "18 April 2024", "deadlineModel": "single-stage", "deadlineDates": ["18 September 2024"], "budgetYearMap": {"2024": 11999999.96}, "expectedGrants": 1, "minContribution": 12000000, "maxContribution": 12000000, "budgetTopicActionMap": {}}]}, "budgetYearsColumns": ["2024"]}, "description": "<SPAN class=\"topicdescriptionkind\">ExpectedOutcome</SPAN>:<p>Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to the following expected outcomes:</p><ul level=\"0\"><li>Increased awareness and improved understanding of the incidence, severity, and impact of late effects in AYA cancer survivors among healthcare providers, patients, caregivers and the general public;</li><li>Researchers, innovators, and professionals from different disciplines and sectors ensure accessibility and re-usability of their data, models, tools and technology to support the UNCAN.eu <sup><a target=_self href=#fn1 id=r1>[1]</a></sup> platform, which is currently in preparation;</li><li>Identification of effective interventions and best practices to support AYA patients and survivors in preventing, reducing and better managing late-effects, promoting optimal health outcomes and overcoming disparities between regions;</li><li>Improved quality of life and long-term outcomes for AYA cancer survivors, including improved physical, emotional, and social well-being.</li> </ul>\n<SPAN class=\"topicdescriptionkind\">Scope</SPAN>:<p>This topic will contribute to the achievement of the Mission\u2019s objective to improve the quality of life of cancer patients, survivors and their families. The focus should be exclusively on adolescent and young adult (AYA, age range 15-39)<sup><a target=_self href=#fn2 id=r2>[2]</a></sup> cancer patients and survivors.</p><p>Each year, more than 150,000 AYA cancers are diagnosed in the EU, and over 1.2 million worldwide. About 300,000 AYA patients live with or beyond cancer in the EU; the majority experience late-effects due to their cancer treatment, including chronic pain, cardiovascular disease, organ and skin alterations, cosmetic sequelae, fertility problems, cognitive and functional impairment, and mental health issues such as depression and anxiety. Survivors may also be at increased risk of second cancers due to the long-term effects of radiation and chemotherapy. The negative impact on education and employment of AYA survivors and in general the financial burden borne by them is also commonly observed.</p><p>Late effects are particularly challenging for AYA cancer survivors, who often experience them during a critical phase of their lives. Late effects are also challenging for caregivers. The considerable progress made in treating AYA cancers has further exposed gaps in the understanding, prevention and management of late-effects, which warrant more targeted pan-European research on AYA cancer survivorship.</p><p>Proposals should focus on one or more cancer types and address only one of the following interventions:</p><ul level=\"0\"><li>Building on data from existing or newly established AYA patient cohorts, ensuring comparability of data across participating countries as appropriate, obtain a thorough assessment by cancer type of the prevalence, specific effect(s), severity, time of onset, relative risk, and risk factors associated to late effects in AYA cancer patients. Attention should be paid also to social and health determinants, including sex, gender, age and other relevant variables, including socio-economic status, living in rural or remote areas and education;</li><li>Develop, test and scale-up evidence-based screening methods for the early detection of late-effects in AYA cancer patients;</li><li>Develop, test and scale up in real-life settings, innovative, holistic approaches and tools (including digital tools), optimising cancer treatment and follow-up regimens to prevent, reduce and/or effectively manage late-effects, including psycho-social aspects. Approaches could focus on education, sports, nutrition, medical follow-up and counselling, for example on mental and physical health, pain management, and wellbeing in general, as well as reproductive matters, including infertility, onco-fertility and fertility options in general and development of effective methods for fertility preservation and guidelines on related counselling.</li> </ul><p>This topic requires direct involvement of cancer patients and survivors, survivor representative organisations, caregivers, and the effective contribution of SSH disciplines and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant results, enhancing the impact of the related research activities.</p><p>The use of participative research models, such as oncology-centred living labs or other approaches to deliver (social) innovation should be considered.</p><p>Due consideration should be given to EU-funded initiatives such as: EU-CAYAS-NET<sup><a target=_self href=#fn3 id=r3>[3]</a></sup>; ERN PaedCan<sup><a target=_self href=#fn4 id=r4>[4]</a></sup>; PanCareFollowUp<sup><a target=_self href=#fn5 id=r5>[5]</a></sup>; PanCareSurPass<sup><a target=_self href=#fn6 id=r6>[6]</a></sup>; EUonQoL<sup><a target=_self href=#fn7 id=r7>[7]</a></sup>; e-Quol<sup><a target=_self href=#fn8 id=r8>[8]</a></sup>; STRONG-AYA<sup><a target=_self href=#fn9 id=r9>[9]</a></sup> <sup><a target=_self href=#fn10 id=r10>[10]</a></sup>.</p><p>The Commission will facilitate coordination. Therefore, successful proposals will be asked to join the 'Quality of Life' cluster for the Mission on Cancer established in 2023<sup><a target=_self href=#fn11 id=r11>[11]</a></sup> and should include a budget for networking, attendance at meetings, and potential joint activities without the prerequisite to give details of these at this stage. Examples: organising joint workshops, establishing best practices, joint communication or citizen engagement activities with projects funded under other clusters and pillars of Horizon Europe, or other EU programmes, as appropriate. The details of joint activities will be defined during the grant agreement preparation phase and during the life of the project.</p>\n<p id=fn1><a  target=_self href=#r1>[1]</a>Under the Mission work programme a Europe-wide research and data platform, UNCAN.eu, will be established, utilising existing, relevant research infrastructures. Once operational, the platform should enable integration of innovative models and technologies with longitudinal patient data, data beyond research, or the health domain, samples and biomarkers for translation to patients.</p><p id=fn2><a  target=_self href=#r2>[2]</a>there is no internationally agreed definition of age range in AYA cancer. Given the purpose of this topic, the target age range should be 15-39 years of age at the time of primary cancer diagnosis. This is broader than the range 15-24 years of age, used in previous topics supported by the Cancer Mission.</p><p id=fn3><a  target=_self href=#r3>[3]</a><a href=\"https://siope.eu/news/news-from-eu-cayas-net-Oct22/\">https://siope.eu/news/news-from-eu-cayas-net-Oct22/</a></p><p id=fn4><a  target=_self href=#r4>[4]</a><a href=\"https://paedcan.ern-net.eu/\">https://paedcan.ern-net.eu/</a></p><p id=fn5><a  target=_self href=#r5>[5]</a><a href=\"https://pancarefollowup.eu/\">Home - PanCareFollowUp</a></p><p id=fn6><a  target=_self href=#r6>[6]</a><a href=\"https://www.pancaresurpass.eu/\">PanCareSurPass \u2013 Implementing the digital Survivorship Passport to improve Person-Centered Survivorship Care</a></p><p id=fn7><a  target=_self href=#r7>[7]</a><a href=\"http://euonqol.eu/\">Quality of Life in Oncology (euonqol.eu)</a></p><p id=fn8><a  target=_self href=#r8>[8]</a>Add ref Funding &amp; Tenders Portal before adoption. Project will start Jan 2024.</p><p id=fn9><a  target=_self href=#r9>[9]</a>https://strongaya.eu/</p><p id=fn10><a  target=_self href=#r10>[10]</a>Applicants are not expected to contact these initiatives before the submission of proposals</p><p id=fn11><a  target=_self href=#r11>[11]</a>In order to address the objectives of the Mission on Cancer, participants will collaborate in project clusters to leverage EU-funding, increase networking across sectors and disciplines, and establish a portfolio of Cancer Mission R&amp;I and policy actions.</p>", "conditions": "<h1><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: medium;\"><span style=\"font-family: Arial;\"><b><span style=\"line-height: 115%;\" lang=\"EN-US\">General conditions</span></b></span></span></span></h1>\r\n<p class=\"MsoNormal\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">1. Admissibility conditions: </span></b><span lang=\"EN-US\">described in </span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex A</span></span></a></span></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> </span><span style=\"color: rgb(0, 0, 0);\"><span lang=\"EN-US\">and </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:&#xA;Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex E</span></span></a></span></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of the Horizon Europe Work Programme General Annexes</span></span></span></p>\n<p style=\"margin-left: 40px;\"><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Proposal page limits and layout:</span></b><span lang=\"EN-US\"> described in Part B of the Application Form available in the Submission System</span></span></span></span></p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">2. Eligible countries: </span></b><span lang=\"EN-US\">described in </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;&#xA;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex B</span></span></a></span></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> </span></span></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">of the Work Programme General Annexes</span></span></span></span><span style=\"mso-ansi-language:EN-US\" lang=\"EN-US\"><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 40px;\"><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:&#xA;minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Horizon Europe Programme Guide</span></span></a></span></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">.</span></span></span></p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b style=\"mso-bidi-font-weight:normal\"><span lang=\"EN-US\">3. Other eligibility conditions:</span></b><span lang=\"EN-US\"> described in </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:&#xA;Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex B</span></span></a></span></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"> <span lang=\"EN-US\">of the Work Programme General Annexes</span></span></span></span></p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b>4. Financial and operational capacity and exclusion: </b>described in </span></span></span><span style=\"mso-bidi-font-weight:bold\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex C</span></span></a></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"> of the Work Programme General Annexes</span></span></span></p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"FR-BE\">5.&nbsp;Evaluation and award:</span></b></span></span></span></p>\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\">\r\n    <p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Award criteria, scoring and      thresholds</span></b><span lang=\"EN-US\"> are      described in </span></span></span></span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex      D</span></span></a></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> </span><span style=\"color: rgb(0, 0, 0);\"><span lang=\"EN-US\">of      the Work Programme General Annexes</span></span></span></span><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n    </li>\r\n</ul>\n<p>The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 3 (Implementation). The cumulative threshold will be 12.</p>\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\">\r\n    <p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Submission and evaluation      processes</span></b><span lang=\"EN-US\"> are      described in </span></span></span></span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex      F</span></span></a></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of      the Work Programme General Annexes and the </span></span></span></span><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Online      Manual</span></span></a><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n    </li>\r\n</ul>\n<p>In order to ensure a balanced Cancer Mission project portfolio and to achieve the expected outcomes of this topic, grants will be awarded not only in order of ranking but also to ensure that:</p><ul level=\"0\"><li>at least one application that fully addresses understanding of late effects in AYA cancer;</li><li>at least one application that fully addresses development of screening methods for early detection of late effects in AYA cancer</li><li>at least one application that fully addresses management of late effects in AYA cancer;</li> </ul><p>are funded provided that these applications attain all thresholds.</p>\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\">\r\n    <p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Indicative timeline for      evaluation and grant agreement: </span></b><span lang=\"EN-US\">described in </span></span></span></span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex      F</span></span></a></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of the Work Programme General Annexes</span></span></span></span><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n    </li>\r\n</ul>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b style=\"mso-bidi-font-weight:normal\"><span lang=\"EN-US\">6. Legal and financial set-up of the grants: </span></b><span lang=\"EN-US\">described in </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:&#xA;minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex G</span></span></a></span></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of the Work Programme General Annexes</span></span></span></span></p>\r\n<p>&nbsp;</p>\n<h1><span style=\"font-size: medium;\"><span style=\"font-family: Arial;\"><b><span style=\"line-height: 115%;\" lang=\"EN-US\">Specific conditions</span></b></span></span><b><span style=\"font-size:12.0pt;mso-bidi-font-size:&#xA;11.0pt;line-height:115%;mso-ansi-language:EN-US\" lang=\"EN-US\"><o:p></o:p></span></b></h1>\r\n<p class=\"MsoNormal\"><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">7. Specific conditions: </span></b><span lang=\"EN-US\">described in the [specific topic of the Work Programme]</span></span></span></span></p>\r\n<p class=\"MsoNormal\">&nbsp;</p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\"><o:p></o:p></span></p>\n<h1><span style=\"font-size: medium;\"><b><span style=\"line-height: 115%;\" lang=\"EN-US\"><span style=\"font-family: Arial;\">Documents</span></span></b></span><b><span style=\"font-size:12.0pt;mso-bidi-font-size:&#xA;11.0pt;line-height:115%;mso-ansi-language:EN-US\" lang=\"EN-US\"><o:p></o:p></span></b></h1>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span style=\"color: rgb(0, 0, 0);\"><b><span lang=\"EN-US\">Call documents:</span></b></span></span></span><b><span lang=\"EN-US\"><o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span style=\"color: rgb(0, 0, 0);\"><span lang=\"EN-US\">Standard application form</span></span><span style=\"color: rgb(128, 128, 128);\"><span lang=\"EN-US\"> &mdash;<i style=\"mso-bidi-font-style:normal\"> call-specific application form is available in the Submission System</i></span></span></span></span><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/af/af_he-ria-ia_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Standard application form (HE RIA, IA)</span></span></a></p>\r\n<p><span style=\"font-size: small;\"><span style=\"color: rgb(0, 0, 0);\"><span lang=\"EN-US\">Standard evaluation form</span></span><span style=\"color: rgb(128, 128, 128);\"><span lang=\"EN-US\"> &mdash;<i style=\"mso-bidi-font-style:normal\"> will be used with the necessary adaptations</i></span></span></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/ef/ef_he-ria-ia_en.pdf\" style=\"font-size: small;\"><span style=\"font-size: small;\"><span lang=\"EN-US\">Standard evaluation form (HE RIA, IA)</span></span></a></p>\r\n<p><span style=\"font-size: small;\"><span style=\"color: rgb(0, 0, 0);\"><span lang=\"EN-US\">MGA</span></span></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/agr-contr/general-mga_horizon-euratom_en.pdf\" style=\"font-size: small;\"><span style=\"font-size: small;\">HE <span lang=\"EN-US\">General MGA v1.0</span></span></a></p>\r\n<p><span style=\"font-size: small;\"><span style=\"color: rgb(64, 64, 64);\" lang=\"EN-US\">Call-specific instructions</span></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"color: rgb(64, 64, 64);\" lang=\"EN-US\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/af/information-on-clinical-studies_he_en.docx\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Information on clinical studies (HE)</span></span></a></span><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/ls-funding-what-do-i-need-to-know_he_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><br />\r\n</span></span></a></p>\n<h2><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Additional documents:</span></b></span></span></span><b><span lang=\"EN-US\"><o:p></o:p></span></b></h2>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-1-general-introduction_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 1. General Introduction</span></span></a></p>\r\n<p><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-12-missions_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 12. Missions</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 13. General Annexes</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Programme Guide</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021R0695\" target=\"_blank\" style=\"font-family: Arial;\"><span style=\"font-size: small;\">HE Framework Programme and Rules for Participation Regulation 2021/695</span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"font-family: Arial;\"><span style=\"color: rgb(64, 64, 64);\" lang=\"EN-US\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021D0764\" target=\"_blank\"><span style=\"font-size: small;\">HE Specific Programme Decision 2021/764</span></a></span></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32018R1046&amp;qid=1535046024012\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">EU Financial Regulation</span></span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/rules-lev-lear-fca_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/aga_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">EU Grants AGA </span>&mdash; Annotated Model Grant Agreement</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">Funding &amp; Tenders Portal Online Manual</span></span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/ftp/tc_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Funding &amp; Tenders Portal Terms and Conditions</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/ftp/privacy-statement_en.pdf\" style=\"font-size: 11pt; font-family: Arial;\"><span style=\"font-size: small;\">Funding &amp; Tenders Portal Privacy Statement</span></a></p>", "supportInfo": "<p><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;&#10;font-weight:normal;mso-bidi-font-weight:bold\"><b><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\" target=\"_blank\">Online Manual</a>&nbsp;</b></span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">is your guide on the procedures from proposal submission to managing your grant.<o:p></o:p></span></p>\r\n<p><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\" target=\"_blank\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\">Horizon Europe Programme Guide</span></b></a><strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;</span></strong><strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif; font-weight: normal;\">contains the detailed guidance to the structure, budget and political priorities of Horizon Europe.</span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/faq;type=undefined;categories=;programme=H2020;actions=;keyword=\" target=\"_blank\">Funding &amp; Tenders Portal FAQ</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;&ndash; find the answers to most frequently asked questions on submission of proposals, evaluation and grant management.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/research-and-innovation/contact/research-enquiry-service_en\" target=\"_blank\">Research Enquiry Service</a></span>&nbsp;</b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.</span></p>\r\n<p><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></p>\r\n<p><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/ncp\" target=\"_blank\">National Contact Points (NCPs)</a>&nbsp;</span></b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; get guidance, practical information and assistance on participation in Horizon Europe. There are also NCPs in many non-EU and non-associated countries (&lsquo;third-countries&rsquo;).<b><o:p></o:p></b></span></p>\r\n<p><a href=\"https://een.ec.europa.eu/\" target=\"_blank\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\">Enterprise Europe Network</span></b></a><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;&#10;color:#003366\">&nbsp;</span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/helpdesks/contact-form\" target=\"_blank\">IT Helpdesk</a></span></b>&nbsp;</span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash;&nbsp;contact the Funding &amp; Tenders Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://www.iprhelpdesk.eu/\" target=\"_blank\">European IPR Helpdesk</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;assists you on intellectual property issues.<br />\r\n<br />\r\n</span><b><a href=\"mailto:research@cencenelec.eu\" target=\"_blank\">CEN-CENELEC Research Helpdesk</a> and <a href=\"https://www.etsi.org/research/helpdesk\" target=\"_blank\">ETSI Research Helpdesk</a></b>&nbsp;<span style=\"font-family: Arial, sans-serif;\">&ndash;&nbsp;</span>the European Standards Organisations&nbsp;advise you how to tackle standardisation in your project proposal.&nbsp;&nbsp;</p>\r\n<p class=\"MsoNormal\" style=\"margin-left:36.0pt\"><o:p></o:p></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://euraxess.ec.europa.eu/sites/default/files/am509774cee_en_e4.pdf\" target=\"_blank\">The European Charter for Researchers and the Code of Conduct for their recruitment</a></span></b></span><span style=\"font-size:&#10;9.0pt;font-family:&quot;Arial&quot;,sans-serif;color:#003366\"> </span><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;color:#003366;font-weight:&#10;normal;mso-bidi-font-weight:bold\">&ndash; consult the general principles and requirements specifying the roles, responsibilities and entitlements of researchers, employers and funders of researchers.</span></strong><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></b></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/partner-search\" target=\"_blank\">Partner Search Services</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;help you find a partner organisation for your proposal.<o:p></o:p></span></p>\r\n<p>&nbsp;</p>", "sepTemplate": "<p>To access the Electronic Submission Service, please click on the submission-button next to the <strong>type of action</strong> and the <strong>type of model grant agreement</strong> that corresponds to your proposal. You will then be asked to confirm your choice, as it cannot be changed in the submission system. Upon confirmation, you will be linked to the correct entry point.</p>\r\n<p>To access existing draft proposals for this topic, please login to the Funding &amp; Tenders Portal and select the My Proposals page of the My Area section.</p>", "links": [{"callIdentifier": "HORIZON-MISS-2024-CANCER-01", "status": "Open", "criterionType": "SubFundingScheme", "criterionTypeDescription": "subfunding schemes", "criterionCode": "HORIZON-RIA", "criterionDescription": "HORIZON  Research and Innovation Actions", "url": "https://ec.europa.eu/research/participants/submission/manage/screen/submission/create-draft/36445?topic=HORIZON-MISS-2024-CANCER-01-05", "startDate": "Apr 18, 2024 12:00:00 AM", "endDate": "Sep 18, 2024 5:00:00 PM", "mgaDescription": "HORIZON Action Grant Budget-Based", "mgaCode": "HORIZON-AG"}], "additionalDossiers": [], "infoPackDossiers": [], "callDetailsJSONItem": {"latestInfos": [{"approvalDate": "Apr 18, 2024 12:00:05 AM", "lastChangeDate": "Apr 18, 2024 12:00:05 AM", "content": "The submission session is now available for: HORIZON-MISS-2024-CANCER-01-01(HORIZON-RIA), HORIZON-MISS-2024-CANCER-01-04(HORIZON-CSA), HORIZON-MISS-2024-CANCER-01-02(HORIZON-CSA), HORIZON-MISS-2024-CANCER-01-03(HORIZON-IA), HORIZON-MISS-2024-CANCER-01-05(HORIZON-RIA), HORIZON-MISS-2024-CANCER-01-06(HORIZON-IA)"}], "hasForthcomingTopics": false, "hasOpenTopics": true, "allClosedTopics": false}}}